New combo therapy aims to improve outcomes for Hard-to-Treat stomach and esophageal cancers
NCT ID NCT05187182
First seen Jan 27, 2026 · Last updated May 07, 2026 · Updated 13 times
Summary
This early-phase trial tests a new drug (CA-4948) combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study aims to find the safest dose and check if the combination helps control the disease. About 42 participants will take part, and those with a certain cancer marker (HER2 positive) will also receive an additional targeted therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.